A Head-To-Head Comparison Of Ixekizumab And Adalimumab In Biologic-Naive Patients With Active Psoriatic Arthritis: 52-Week Efficacy And Safety Outcomes From A Randomized, Open-Label, Blinded Assessor Study
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY（2020）
关键词
active psoriatic arthritis,adalimumab,ixekizumab,blinded assessor study,head-to-head,biologic-naive,open-label
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要